printemailclick to share buttonfacebooktwitterlinkedin
Gynecologic Cancer Evidence-based Series (EBS) and Practice Guidelines (PG)

Gynecologic cancers include the ovary and cervix.

The Gynecologic Cancer Disease Site Group (Gynecologic DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.  The titles of the reports produced to date by the DSG are listed below, with links to the PDF versions of those reports.    

The PEBC has a formal and standardized process to ensure the currency of each document. This process guides clinical experts to assess a document’s current status and relevance (please see the PEBC Assessment & Review Protocol for more information). A final status statement is added to the document when this review process is complete. The current status of each guidance document is noted beside the title and link as outlined below:

  • Documents listed as CURRENT are 3 years old or less, up-to-date, and can be used for decision making.
  • Documents listed as IN REVIEW are undergoing assessment for currency and relevance.  The DSG/GDG has determined that it is still appropriate for this document to continue to be available while this updating process unfolds.
  • Documents that are listed as “FOR EDUCATION AND INFORMATION PURPOSES” are documents for which no further updates are planned and whose recommendations may no longer be consistent with recent evidence.  They may be of educational, historical, clinical, or system interest.

If you have any questions regarding a document that is “In Review,” please contact the PEBC ( ) or the lead author of the document. 

  • Organizational Guideline for Gynecologic Oncology Services in Ontario
    4-11 EBS: June 2013
    Status: CURRENT


  • Sentinel Lymph Node Biopsy in Vulvar Cancer
    4-17 EBS: July 2014
    Status: IN REVIEW


  • Systemic Therapy for Recurrent Epithelial Ovarian Cancer
    Guideline 4-3 Version 4: July 2017
    Status: CURRENT
  • Follow-up of Patients who are Clinically Disease-free after Primary Treatment for Fallopian Tube, Primary Peritoneal, and Epithelial Ovarian Cancer
    Guideline 4-22: November 2015
    Status: CURRENT
  • Management of Suspicious Adnexal Mass
    4-15 Version 2 EBS: September 2016 
    Status: CURRENT 
  • Management Options for Women with a Hereditary Predisposition to Ovarian Cancer
    4-4 ES: June 2004 Update
    Status: IN REVIEW
  • Adjuvant Care for Stage 1 Ovarian Cancer
    4-13 Version 2 PG: June 2016 
    Status: CURRENT 


  • Follow-up after Primary Therapy for Endometrial Cancer
    4-9 Version 2 EBS: June 2017 
    Status: CURRENT 
  • Systemic Therapy for Advanced or Recurrent Endometrial Cancer, and Advanced or Recurrent Uterine Papillary Serous Carcinoma
    4-8 Version 3 PG: June 2017
    Status: CURRENT


  • Follow-up for Cervical Cancer
    Guideline 4-16 Version 2: May 2015
    Status: CURRENT
  • Systemic Therapy for Recurrent, Metastatic, or Persistent Cervical Cancer
    4-20 Version 2 EBS: November 2014
    Status: CURRENT

For Education and Information Purposes 

  • Adjuvant Hormonal Therapy in Stage I Endometrial Cancer
  • Screening Postmenopausal Women for Ovarian Cancer
  • Screening High Risk Women for Ovarian Cancer
  • Adjuvant Radiotherapy in Women with Stage I Endometrial Cancer
  • First-line Chemotherapy for Postoperative Patients with Stage II, III or IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
  • Alternative and Complementary Therapy in the Prevention and Management of Gynecologic Cancers
  • Systemic Therapy for Advanced, Recurrent, or Metastatic Uterine Sarcoma
    • 4-12 EBS
      Based on the classification from the FIGO COMMITTEE 2009, uterine sarcomas include four different types: LMS, endometrial stromal sarcoma, adenosarcoma, and carcinosarcoma; the pathology, staging, and clinical management of these four types are very different. Endometrial stromal sarcoma and carcinosarcoma are most often treated as epithelial cancers, and adenosarcoma is considered insensitive to chemotherapy with surgery remaining the mainstay of therapy. Please refer to the updated Sarcoma DSG guideline EBS 11-11 , which focuses only on the role of systemic chemotherapy for uterine leiomyosarcoma and which replaces this ARCHIVED guideline.
  • The Role of Intraperitoneal Chemotherapy in the First-line Treatment of Women with Stage III Epithelial Ovarian Cancer

Program in Evidence-Based Care (PEBC)
McMaster University, Juravinski Site
G Wing, 2nd Floor
711 Concession Street
Hamilton, Ontario, Canada
L8V 1C3

Phone: 905.527.4322 ext. 42822
Fax: 905.526.6775
Last modified: Fri, Jul 28, 2017
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?